Kodiak Sciences Inc.

NasdaqGM:KOD 주식 리포트

시가총액: US$2.6b

Kodiak Sciences 과거 순이익 실적

과거 기준 점검 0/6

Kodiak Sciences의 연간 평균 수익은 4.7%였으며, Biotechs 산업의 수익은 연간 30.5% 증가했습니다.

핵심 정보

4.74%

순이익 성장률

5.94%

주당순이익(EPS) 성장률

Biotechs 산업 성장률17.04%
매출 성장률n/a
자기자본이익률-205.76%
순이익률n/a
최근 순이익 업데이트31 Mar 2026

최근 과거 실적 업데이트

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
분석 기사 • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
분석 기사 • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
분석 기사 • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
분석 기사 • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
분석 기사 • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

매출 및 비용 세부 내역

Kodiak Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGM:KOD 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Mar 260-23150187
31 Dec 250-23052182
30 Sep 250-21754169
30 Jun 250-20057150
31 Mar 250-19158140
31 Dec 240-17661126
30 Sep 240-19263141
30 Jun 240-19867145
31 Mar 240-23369180
31 Dec 230-26071206
30 Sep 230-27172216
30 Jun 230-29872241
31 Mar 230-30972248
31 Dec 220-33474268
30 Sep 220-35773287
30 Jun 220-34767282
31 Mar 220-31259253
31 Dec 210-26750217
30 Sep 210-22042179
30 Jun 210-18938152
31 Mar 210-15933128
31 Dec 200-13329107
30 Sep 200-1022283
30 Jun 200-781864
31 Mar 200-641552
31 Dec 190-471238
30 Sep 190-461132
30 Jun 190-441026
31 Mar 190-41821
31 Dec 180-41819
30 Sep 180-38621
30 Jun 180-32519
31 Mar 180-31521
31 Dec 170-28322

양질의 수익: KOD 은(는) 현재 수익성이 없습니다.

이익 마진 증가: KOD는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: KOD는 수익성이 없지만 지난 5년 동안 연평균 4.7%의 속도로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 KOD의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: KOD은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: KOD는 현재 수익성이 없으므로 자본 수익률이 음수(-205.76%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/11 06:10
종가2026/05/11 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Kodiak Sciences Inc.는 18명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research